Recent findings concerning thiazolidinediones in the treatment of diabetes.
about
Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse modelPioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemWeight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis.Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line.Insulin-Mimetic Action of Rhoifolin and Cosmosiin Isolated from Citrus grandis (L.) Osbeck Leaves: Enhanced Adiponectin Secretion and Insulin Receptor Phosphorylation in 3T3-L1 Cells.Obesity, insulin resistance and free fatty acids.Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazoneThe fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesEffect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines.Obesity and free fatty acids.Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance.Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.Effects of diet and exercise on metabolic disturbances in high-fat diet-fed mice.Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Potent PPARγ Ligands from Swietenia macrophylla Are Capable of Stimulating Glucose Uptake in Muscle Cells.A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation.Renal and vascular mechanisms of thiazolidinedione-induced fluid retention.Characterization of telmisartan-derived PPARγ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment.High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers?Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
P2860
Q28829254-06CE25FC-20A0-4E72-B50E-785DC2E5C51FQ30848657-EE89C678-8D90-4F05-8824-2DE30AE7228BQ33288486-9055730E-FA4B-4E1C-BCFD-6B40C3FEAC4DQ34068749-58C78322-EE1F-4B98-95DD-A198F348A356Q34540220-CDED1F5C-2421-4404-9A6B-49902F68BD2FQ34786163-562BEFAD-5507-476C-9F07-566BDC00FF5BQ35155184-AC58FAD6-1C40-4757-A895-C08F541527D8Q35204838-E90FD298-F9DC-4007-B724-7610185DB37CQ35591020-40222476-7CAB-4AD1-8F50-6708F823D7EAQ35688754-308CF807-939D-4F80-B935-A039E2EBADE1Q36109894-7AA84629-D67D-466B-A0D4-0B0DF9789040Q36410781-034F5ECB-F6A0-4DBA-8886-ADEA7093FD0BQ36812788-4A1FA5B2-43FE-4328-BFFF-2B24F526C258Q36846138-982AF966-F486-44A2-95D2-4241A7CDC0CBQ37001269-3557DBB0-3B30-433C-BABA-901F06CACEE2Q37112535-0FDD1026-8C6D-4524-B91D-57BE11DB446DQ37192464-93FBA332-90F2-4799-A32D-D9F9F45DDC9AQ37345631-238FF6C4-9835-47F5-ACB6-CCC20ED680B6Q37356735-28FF298D-926C-4C86-A528-12E0FE3A26C1Q37724195-4C71E605-2E91-454C-AB1E-C94D3067E2F7Q38809165-E51D3928-67D0-4982-9EB3-8B8F7A2B9D20Q39535230-4F61BEF1-DD67-4CB9-A2DB-542D95BB4CB8Q40048496-5308D0CC-344C-436A-8D94-0B23DB05EE16Q42811249-F344F5D0-7495-47B6-BE27-753EFDC9A7B3Q43135202-5B8F0D27-11BF-4730-BCC0-16BD25795EF2Q46959422-B579BF15-A9C9-4AD5-94BE-8008AFFC033AQ51478140-43F5B8A8-EB06-4F88-B667-896496E83F16
P2860
Recent findings concerning thiazolidinediones in the treatment of diabetes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@ast
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@en
type
label
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@ast
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@en
prefLabel
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@ast
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@en
P2860
P1476
Recent findings concerning thiazolidinediones in the treatment of diabetes.
@en
P2093
Guenther Boden
Meijuan Zhang
P2860
P304
P356
10.1517/13543784.15.3.243
P407
P577
2006-03-01T00:00:00Z